• 1
    A.P.A. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
  • 2
    Wonderlich SA, Gordon KH, Mitchell JE, Crosby RD, Engel SG. The validity and clinical utility of binge eating disorder. Int J Eat Disord 2009; 42: 687705.
  • 3
    Hudson JI, Hiripi E, Pope HG Jr, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry 2007; 61: 348358.
  • 4
    Hudson JI, Lalonde JK, Berry JM, Pindyck LJ, Bulik CM, Crow SJ, et al. Binge-eating disorder as a distinct familial phenotype in obese individuals. Arch Gen Psychiatry 2006; 63: 313319.
  • 5
    Yager J. Binge eating disorder: The search for better treatments. Am J Psychiatry 2008; 165: 46.
  • 6
    McElroy SL, Guerdjikova AI, Mori N, O'Melia AM. Pharmacolgical management of binge eating disorder: Current and emerging treatment options. Therapeutics Clin Risk Manage 2012; 8: 219241.
  • 7
    Burt J. American Chemical Society - 240th national meeting - chemistry for preventing and combating disease: part 1. IDrugs 2010; 13: 669672.
  • 8
    Hillemacher T, Heberlein A, Muschler MA, Bleich S, Frieling H. Opioid modulators for alcohol dependence. Expert Opin Investig Drugs 2011; 20: 10731086.
  • 9
    Boggiano MM, Chandler PC, Viana JB, Oswald KD, Maldonado CR, Wauford PK. Combined dieting and stress evoke exaggerated responses to opioids in binge-eating rats. Behav Neurosci 2005; 119: 12071214.
  • 10
    Cottone P, Sabino V, Steardo L, Zorrilla EP. Opioid-dependent anticipatory negative contrast and binge-like eating in rats with limited access to highly preferred food. Neuropsychopharmacology 2008; 33: 524535.
  • 11
    Nathan PJ, Bullmore ET. From taste hedonics to motivational drive: Central mu-opioid receptors and binge-eating behaviour. Int J Neuropsychopharmacol 2009; 12: 9951008.
  • 12
    Berner LA, Bocarsly ME, Hoebel BG, Avena NM. Pharmacological interventions for binge eating: Lessons from animal models, current treatments, and future directions. Curr Pharm Des 2011; 17: 11801187.
  • 13
    Ignar DM, Goetz AS, Noble KN, Carballo LH, Stroup AE, Fisher JC, et al. Regulation of ingestive behaviors in the rat by GSK1521498, a novel micro-opioid receptor-selective inverse agonist. J Pharmacol Exp Ther 2011; 339: 2434.
  • 14
    Drewnowski A, Krahn DD, Demitrack MA, Nairn K, Gosnell BA. Naloxone, an opiate blocker, reduces the consumption of sweet high-fat foods in obese and lean female binge eaters. Am J Clin Nutr 1995; 61: 12061212.
  • 15
    Chamberlain SR, Mogg K, Bradley BP, Koch A, Dodds CM, Tao WX, et al. Effects of mu opioid receptor antagonism on cognition in obese binge-eating individuals. Psychopharmacology (Berl) 2012.
  • 16
    Mitchell JE, Christenson G, Jennings J, Huber M, Thomas B, Pomeroy C, Morley J. A placebo-controlled, double-blind crossover study of naltrexone hydrochloride in outpatients with normal weight bulimia. J Clin Psychopharmacol 1989; 9: 9497.
  • 17
    Alger SA, Schwalberg MD, Bigaouette JM, Michalek AV, Howard LJ. Effect of a tricyclic antidepressant and opiate antagonist on binge-eating behavior in normoweight bulimic and obese, binge-eating subjects. Am J Clin Nutr 1991; 53: 865871.
  • 18
    Jonas JM, Gold MS. Naltrexone treatment of bulimia: Clinical and theoretical findings linking eating disorders and substance abuse. Adv Alcohol Subst Abuse 1987; 7: 2937.
  • 19
    Marrazzi MA, Bacon JP, Kinzie J, Luby ED. Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa. Int Clin Psychopharmacol 1995; 10: 163172.
  • 20
    Raingeard I, Courtet P, Renard E, Bringer J. Naltrexone improves blood glucose control in type 1 diabetic women with severe and chronic eating disorders. Diabetes Care 2004; 27: 847848.
  • 21
    Marrazzi MA, Markham KM, Kinzie J, Luby ED. Binge eating disorder: Response to naltrexone. Int J Obes Relat Metab Disord 1995; 19: 143145.
  • 22
    Neumeister A, Winkler A, Wober-Bingol C. Addition of naltrexone to fluoxetine in the treatment of binge eating disorder. Am J Psychiatry 1999; 156: 797.
  • 23
    First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition with Psychotic Screen (SCID-I/P W/ PSY SCREEN). New York, NY: Biometric Research; New York State Psychiatric Institute; 2002.
  • 24
    Beck AT, Steer RA, Brown GK. BDI-II, Beck depression inventory: Manual, 2nd ed. San Antonio, TX: Pearson; 1996.
  • 25
    Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989; 46: 10061011.
  • 26
    Guy W. Clinical Global Improvement Scale. ECDEU Assessment Manual for Psychopharmacology - Revised (DHEW Publ No ADM 76-338). Rockville, MD: U.S. Department of Health, Education, and Welfare; 1976. pp. 21822.
  • 27
    Stunkard AJ, Messick S. Eating Inventory Maual. San Antonio, TX: Pearson; 1988.
  • 28
    White MA, Whisenhunt BL, Williamson DA, Greenway FL, Netemeyer RG. Development and validation of the food-craving inventory. Obes Res 2002; 10: 107114.
  • 29
    Posner K. Columbia-Suicide Severity Rating Scale (C-SSRS). Columbia University Medical Center; [Accessed 10/19/11]; Available at:
  • 30
    Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. Hoboken, NJ: Wiley; 2004.
  • 31
    Gibbons RD, Hedeker D, Elkin I, Waternaux C, Kraemer HC, Greenhouse JB, et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset. Arch Gen Psychiatry 1993; 50: 739750.
  • 32
    Hudson JI, McElroy SL, Raymond NC, Crow S, Keck PE Jr, Carter WP, et al. Fluvoxamine in the treatment of binge-eating disorder: A multicenter placebo-controlled, double-blind trial. Am J Psychiatry 1998; 155: 17561762.
  • 33
    McElroy SL, Hudson JI, Capece JA, Beyers K, Fisher AC, Rosenthal NR, for the Topiramate Binge Eating Disorder Research Group. Topiramate for the treatment of binge eating disorder associated with obesity: A placebo-controlled study. Biol Psychiatry 2007; 61: 10391048.
  • 34
    Lee MW, Fujioka K. Naltrexone for the treatment of obesity: review and update. Expert Opin Pharmacother 2009; 10: 18411845.
  • 35
    Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376: 595605.
  • 36
    Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O'Neil PM, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 2011; 19: 110120.
  • 37
    Todtenkopf MS, O'Neill KS, Kriksciukaite K, Turncliff RZ, Dean RL, Ostrovsky-Day I, Deaver DR. Route of administration affects the ability of naltrexone to reduce amphetamine-potentiated brain stimulation reward in rats. Addict Biol 2009; 14: 408418.
  • 38
    Lightlake Therapeutics Inc. Lightlake Therapeutics Inc. Announces Positive Preliminary Phase II Clinical Trial Results of Binge Eating Disorder Treatment. 2012 [cited 2012 July 6]; Available at:
  • 39
    Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
  • 40
    Spiegelhalter DJ, Abrams KR, Myle JP. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. New York, NY: Wiley, 2004.
  • 41
    O'Malley SS, Sinha R, Grilo CM, Capone C, Farren CK, McKee SA, et al. Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: A randomized controlled trial. Alcohol Clin Exp Res 2007; 31: 625634.